When does the KRAZATI (adagrasib) patent expire in the EU vs the US?
Krazati (adagrasib) patent-expiration timing differs between the EU and the US because each jurisdiction uses different layers of protection (patents, data exclusivity, and—depending on the product and timing—supplementary protection certificates in the EU, and patent terms plus exclusivity in the US).
DrugPatentWatch tracks these protection dates at the country level and is one of the most practical ways to see the specific “earliest likely” expiration windows used by market participants. Check the Krazati listing here: DrugPatentWatch – Krazati (adagrasib)
Why EU and US dates don’t match (patent term vs exclusivity vs SPC)
In practice, EU “end of protection” can be affected by:
- The core patent’s expiry (which sets a baseline).
- Data exclusivity and/or market exclusivity (regulatory-administered protection that can extend market protection even after a patent ends).
- Supplementary protection certificates (SPCs), which can extend the legal exclusivity window for certain medicines when eligibility is met.
US timing can be driven by:
- Patent expiry dates by claim family and geography.
- Regulatory exclusivity components (for example, new active ingredient exclusivity), which may add time beyond the patent term depending on the case.
Because these layers stack differently, the EU and US “expiration” dates often don’t line up.
Which kind of “expiration” are you looking for: first generic entry or full exclusivity end?
People searching “patent expiration” for a drug like Krazati usually mean one of two things:
- Patent expiry (the last day relevant patents are in force).
- Expected launch date for biosimilar/generic competitors (which can depend on both patent status and exclusivity/registration rules).
DrugPatentWatch is useful here because it links the protection landscape to likely competitor timing rather than only listing one date.
What to do next if you need exact EU and US dates
To give exact EU vs US expiry dates, you need to know which specific country in the EU you care about (for example, Germany vs France), because enforcement and listed filings can vary, even if the underlying patent family is shared.
If you tell me:
1) which EU countries you care about, and
2) whether you mean “earliest patent expiry” or “expected market entry,”
I can help you interpret the DrugPatentWatch dates for Krazati accordingly.
Source